These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review. Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578 [TBL] [Abstract][Full Text] [Related]
66. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849 [TBL] [Abstract][Full Text] [Related]
67. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]
68. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302 [TBL] [Abstract][Full Text] [Related]
69. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Schulenburg A; Turetschek K; Wrba F; Vogelsang H; Greinix HT; Keil F; Mitterbauer M; Kalhs P Ann Hematol; 2004 Feb; 83(2):101-6. PubMed ID: 14615909 [TBL] [Abstract][Full Text] [Related]
70. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
71. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579 [TBL] [Abstract][Full Text] [Related]
72. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation]. Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621 [TBL] [Abstract][Full Text] [Related]
73. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414 [TBL] [Abstract][Full Text] [Related]
74. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more]. Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977 [TBL] [Abstract][Full Text] [Related]
75. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation. Du J; Liu J; Gu J; Zhu P Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570 [TBL] [Abstract][Full Text] [Related]
76. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Vokurka S; Steinerova K; Karas M; Koza V Bone Marrow Transplant; 2009 Nov; 44(9):601-5. PubMed ID: 19349956 [TBL] [Abstract][Full Text] [Related]
77. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080 [TBL] [Abstract][Full Text] [Related]
78. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902 [TBL] [Abstract][Full Text] [Related]
79. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Nachbaur D; Clausen J; Kircher B Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430 [TBL] [Abstract][Full Text] [Related]
80. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Lawton CA; Cohen EP; Murray KJ; Derus SW; Casper JT; Drobyski WR; Horowitz MM; Moulder JE Bone Marrow Transplant; 1997 Dec; 20(12):1069-74. PubMed ID: 9466280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]